eeking to address rising prescription drug costs, UnitedHealthcare (UNH) said Tuesday that it will pass along some rebates that the big insurer receives from drug makers, a move that may provide relief to a small portion of consumers, but was also criticized for failing to address the larger problem of rising medicine prices.

Starting next year, the insurer will redirect a majority of rebates for around 7.5 million people, and expects to reduce costs from just a few dollars to more than $1,000 for each prescription. However, the initiative will not include an estimated 18.6 million consumers who are covered by so-called self-insured plans, in which employers pay for health care benefits.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Assuming Mr hill is correct in this – “The problem with the model is the vast majority of rebates are generated by a small number of beneficiaries taking expensive brand and specialty drugs. ” – would that explain why the PBMs have gotten less attention until now? This really only took off with EpiPen and Heather Bresch, as I remember.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.